“Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis”. 2024. SKIN The Journal of Cutaneous Medicine 8 (6): s441. https://doi.org/10.25251/skin.8.supp.441.